PlainRecalls
FDA Drug Low Class III Terminated

Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDC 0378-3002-77) and b) 500-count bottles (NDC 0378-3002-05), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Reported: October 28, 2020 Initiated: October 2, 2020 #D-0049-2021

Product Description

Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDC 0378-3002-77) and b) 500-count bottles (NDC 0378-3002-05), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Reason for Recall

Out-of-specification organic impurity results obtained during routine stability testing.

Details

Units Affected
10,695 bottles
Distribution
Nationwide within the United States
Location
Morgantown, WV

Frequently Asked Questions

What product was recalled?
Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDC 0378-3002-77) and b) 500-count bottles (NDC 0378-3002-05), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.. Recalled by Mylan Pharmaceuticals Inc.. Units affected: 10,695 bottles.
Why was this product recalled?
Out-of-specification organic impurity results obtained during routine stability testing.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 28, 2020. Severity: Low. Recall number: D-0049-2021.